Compare
Savara Inc vs Heron Therapeutics, Inc. vs Macrogenics Inc vs Assembly Biosciences, Inc.
| Latest fiscal year | Savara Inc SVRA | Heron Therapeutics, Inc. HRTX | Macrogenics Inc MGNX | Assembly Biosciences, Inc. ASMB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $154.90M | $149.50M | $72.30M |
| Revenue growth (YoY) | n/a | +7.4% | -0.3% | +153.5% |
| Gross margin | n/a | 73.3% | n/a | n/a |
| Operating margin | n/a | -1.6% | -48.7% | -16.8% |
| Net margin | n/a | -13.0% | -49.9% | -8.5% |
| Net income | -$118.84M | -$20.20M | -$74.62M | -$6.12M |
| EPS (Diluted) | -$0.53 | -$0.12 | -$1.18 | -$0.55 |
| Operating cash flow | -$101.04M | -$27.59M | -$81.04M | -$41.09M |
| Free cash flow | -$101.06M | -$27.91M | -$82.95M | -$41.16M |
| Cash & equivalents | $33.18M | $28.65M | $57.22M | $58.45M |
| Total assets | $253.44M | $255.88M | $256.85M | $257.59M |
| Total liabilities | $50.30M | $241.54M | $201.25M | $50.84M |
| Shareholders' equity | $203.13M | $14.33M | $55.59M | $206.75M |
| Return on year-end equity | -58.5% | -140.9% | -134.2% | -3.0% |
| Shares outstanding | 204.57M | 188.31M | 63.32M | 15.86M |
Revenue, most recent five fiscal years
| Fiscal year | Savara Inc | Heron Therapeutics, Inc. | Macrogenics Inc | Assembly Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $257.0K Ended 2020-12-31 | $154.90M Ended 2025-12-31 | $149.50M Ended 2025-12-31 | $72.30M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $144.28M Ended 2024-12-31 | $149.96M Ended 2024-12-31 | $28.52M Ended 2024-12-31 |
| 2 years earlier | n/a | $127.04M Ended 2023-12-31 | $58.75M Ended 2023-12-31 | $7.16M Ended 2023-12-31 |
| 3 years earlier | n/a | $107.67M Ended 2022-12-31 | $151.94M Ended 2022-12-31 | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $86.35M Ended 2021-12-31 | $77.45M Ended 2021-12-31 | $6.25M Ended 2021-12-31 |